Resistance of Schistosoma mansoni to praziquantel: is there a problem? (Q35021630)

5 August 2017

1 reference

title

Resistance of Schistosoma mansoni to praziquantel: is there a problem? (English)

1 reference

5 August 2017

0 references

1 reference

Michael J Doenhoff

1

0 references

author name string

John R Kusel

series ordinal

2

1 reference

PubMed ID

12474468

5 August 2017

Gerald C Coles

series ordinal

3

1 reference

PubMed ID

12474468

5 August 2017

Donato Cioli

series ordinal

4

1 reference

5 August 2017

1 September 2002

1 reference

Transactions of the Royal Society of Tropical Medicine and Hygiene

5 August 2017

1 reference

5 August 2017

96

1 reference

5 August 2017

465-469

1 reference

5 August 2017

5

1 reference

The development of resistance to anthelmintics: a perspective with an emphasis on the antischistosomal drug praziquantel

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Comparison of different chemotherapy strategies against Schistosoma mansoni in Machakos District, Kenya: effects on human infection and morbidity

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Chemotherapy of schistosomiasis: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Praziquantel: is there real resistance and are there alternatives?

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Drug resistance in schistosomes.

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Drug resistance or tolerance in schistosomes?

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Sustainable use of anthelmintics in grazing animals

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Defining resistance in Schistosoma

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Tolerance of Kenyan Schistosoma mansoni to oxamniquine.

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Natural versus drug-induced resistance in Schistosoma mansoni infection

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Is Schistosomicidal Chemotherapy Sub-curative? Implications for Drug Resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Evidence for an immune-dependent action of praziquantel on Schistosoma mansoni in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Praziquantel and the control of schistosomiasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

The USAID/Government of Egypt's Schistosomiasis Research Project (SRP).

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific.

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Schistosome resistance to praziquantel: Fact or artifact?

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Schistosoma mansoni: maturation rate and drug susceptibility of different geographic isolates.

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Drug resistance in human helminths: current situation and lessons from livestock

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence.

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Therapeutic evaluation of two different dose regimens of praziquantel in a recent Schistosoma mansoni focus in Northern Senegal

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel.

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers.

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Efficacy of alternating therapy with oxamniquine and praziquantel to treat Schistosoma mansoni in children following failure of first treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Schistosome calcium channel beta subunits. Unusual modulatory effects and potential role in the action of the antischistosomal drug praziquantel

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Praziquantel--its use, cost and possible development of resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Detection of praziquantel resistance in schistosomes.

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

In vitro responses of praziquantel-resistant and -susceptible Schistosoma mansoni to praziquantel

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Biological characteristics of praziquantel-resistant and -susceptible isolates of Schistosoma mansoni

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

The impact of refugia on the development of thiabendazole resistance in Haemonchus contortus

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Heterogeneities in anti-schistosome humoral responses following chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Alterations in cytochrome-c oxidase expression between praziquantel-resistant and susceptible strains of Schistosoma mansoni.

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Schistosoma mansoni: genetic complementation analysis shows that two independent hycanthone/oxamniquine-resistant strains are mutated in the same gene.

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Efficacy of praziquantel against Schistosoma mansoni in northern Senegal

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

A quantitative analysis of the diagnostic value of diethylcarbamazine provocation in endemic Wuchereria bancrofti infection

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

An international initiative on praziquantel use.

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Schistosoma mansoni: Reduced efficacy of chemotherapy in infected T-cell-deprived mice

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Schistosoma mansoni: chemotherapy of infections of different ages

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni.

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Oxamniquine cures Schistosoma mansoni infection in a focus in which cure rates with praziquantel are unusually low.

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

The efficacy of praziquantel against Schistosoma mansoni infection in Ndombo, northern Senegal

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Randomly amplified polymorphic DNA (RAPD) polymerase chain reaction assay for identification of Schistosoma mansoni strains sensitive or tolerant to anti-schistosomal drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Praziquantel-induced tegumental damage in vitro is diminished in schistosomes derived from praziquantel-resistant infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

Stability and reproductive fitness of Schistosoma mansoni isolates with decreased sensitivity to praziquantel

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2802%2990405-0

7 January 2021

10.1016/S0035-9203(02)90405-0

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

12474468